SR 17018 — Use & Safety

Product Overview

ÆTHER SR 17018 capsules contain precisely measured SR 17018 — a synthetic biased mu-opioid receptor agonist developed as a next-generation research compound. SR 17018 is not a recreational substance. It is a harm reduction tool used by people seeking to discontinue conventional opioids — including fentanyl, heroin, methadone, buprenorphine, and prescription opioids — without experiencing acute withdrawal. It produces analgesia and withdrawal suppression without euphoria, significantly reducing its reinforcing potential. For adults 21 years of age or older only. Read all warnings before use.

Active Ingredient

SR 17018

Route

Oral — swallow whole

Mechanism

Biased G-protein agonism
Minimal beta-arrestin-2 recruitment

Key Properties

Analgesia without euphoria
Withdrawal suppression
Tolerance reversal

Protocol Duration

Typically 1–3 weeks, tapering

Classification

Research compound
Not FDA-approved for human use

Potential Benefits

SR 17018 occupies a unique position in harm reduction. Unlike methadone or buprenorphine — which substitute one opioid dependence for another in a maintenance model — SR 17018 appears to actively reverse opioid tolerance and suppress withdrawal simultaneously, allowing people to step off conventional opioids without the agonizing withdrawal syndrome that typically drives relapse. Because it lacks the euphoric reinforcement of conventional opioids, it does not create the reward cycle that sustains dependence. Community reports since approximately 2024 have described successful cessation from some of the most difficult opioids to quit — including fentanyl and long-term methadone — using SR 17018 protocols.

Withdrawal Suppression

Satisfies opioid receptors sufficiently to prevent acute withdrawal during the cessation period

Tolerance Reversal

Preclinical data shows SR 17018 actively resets receptor-level adaptations — walking tolerance back toward baseline

No Euphoric Reinforcement

Non-euphoric profile means it does not substitute one addiction for another — no reward cycle to maintain

Reduced Respiratory Risk

Preclinical safety window approximately 10× wider than morphine for respiratory depression

Analgesia

Effective pain relief without the sedation, euphoria, or dependence risk of conventional opioids

Opioid Cessation

Community protocols report successful discontinuation from fentanyl, heroin, methadone, and prescription opioids

Dosing Protocol

SR 17018 is not used as a single-session substance — it is administered on a scheduled maintenance protocol, typically over one to three weeks, with gradual tapering as the underlying opioid dependence resolves. The following protocol reflects community reports and is not a clinically validated medical protocol. Individual response varies. Begin on the lower end and adjust based on withdrawal symptom control.

Phase 1 — Induction

25–30 mg

Every 4–6 hours · Days 1–7
Initiate as acute withdrawal begins. Adjust timing to symptom control. Do not exceed 6 doses per 24 hours.

Phase 2 — Stabilization

15–25 mg

Every 6–8 hours · Days 7–14
Reduce dose and extend intervals as tolerance reversal proceeds and withdrawal symptoms diminish.

Phase 3 — Taper

10–15 mg

Every 8–12 hours · Weeks 2–3
Continue tapering until SR 17018 can be discontinued without withdrawal recurrence.

These are community-reported protocols — not clinically validated dosing guidelines. Individual response, prior opioid history, and tolerance level significantly affect the appropriate protocol. Do not use SR 17018 alongside conventional opioids. Monitor for signs of over-sedation. If unsure, begin at the lower end of each phase.

Ingredients

SR 17018
Vegetable capsule

Does not contain conventional opioids, benzodiazepines, or adulterants.

Storage & Handling

Storage

Store in a cool, dark, dry place
Keep between 15–25°C (59–77°F)
Keep tightly sealed
Refrigeration acceptable but not required

Handling

Keep out of reach of children and animals
Do not expose to excessive heat or moisture
Do not crush or open capsules
Use within 24 months of manufacture

Warnings

⚠ Critical — Tolerance Reversal Risk

SR 17018 actively reverses opioid tolerance. After completing a course of SR 17018, your tolerance to conventional opioids — fentanyl, heroin, morphine, oxycodone — will be substantially or completely reduced. Resuming conventional opioids at your previous dose following SR 17018 treatment carries a greatly elevated risk of fatal overdose. This risk has resulted in documented fatalities in community reports. If you resume opioid use after SR 17018, treat yourself as opioid-naive and start with a fraction of your previous dose.

⚠ Warning — Research Compound

For adults 21 years of age or older only. Keep out of reach of children and animals.
SR 17018 has not been approved for human use by the FDA and has not completed human clinical trials. Its full safety profile in humans has not been established.
Do not use if pregnant or nursing.
Do not use if you have respiratory disease, severe asthma, or sleep apnea. All opioid receptor agonists carry some degree of respiratory depression risk.
Do not use if you have severe hepatic or renal impairment.
Do not drive, operate machinery, or perform tasks requiring full alertness while using SR 17018.
Use naloxone (Narcan) as a backup. Although SR 17018's respiratory safety margin is improved over conventional opioids, naloxone should be available during the induction phase.

⚠ Critical — Drug Interactions

Do not combine with conventional opioids (fentanyl, heroin, morphine, oxycodone, methadone, buprenorphine) during the SR 17018 protocol. Combining opioid receptor agonists may cause unpredictable CNS and respiratory depression.
Do not combine with benzodiazepines (Xanax, Valium, Klonopin, etc.). The combination of any opioid agonist with benzodiazepines dramatically increases the risk of fatal respiratory depression.
Do not combine with alcohol. CNS and respiratory depression are potentiated.
Do not combine with other CNS depressants including sleep aids, muscle relaxants, or antihistamines with sedating properties.
Disclose all current medications to a healthcare provider if possible before beginning the protocol.

⚠ Known Risks

Residual opioid withdrawal symptoms during the induction phase
Mild sedation or dizziness, particularly at higher doses
Nausea during the first 24–48 hours of use
Constipation with extended use
Unknown long-term effects in humans (preclinical compound)
Fatal overdose risk if conventional opioids are resumed at previous doses after treatment

Emergency Contact

National Poison Control Center

1-800-222-1222

In case of emergency or accidental ingestion

Call 911 immediately and administer naloxone
if breathing problems or loss of consciousness occur.

Legal Disclaimer

Purchaser assumes all responsibility for legal compliance and proper use. Manufacturer is not responsible for misuse, improper storage, use inconsistent with provided safety guidance, adverse reaction whether foreseeable or unforeseeable, allergic reaction, or unauthorized use.

Not evaluated by the U.S. Food & Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. SR 17018 is a research compound that has not completed human clinical trials. Use constitutes self-experimentation with an unapproved substance.

Manufactured By

ÆTHER
Washtenaw County, MI
aethera2.com
@AetherA2

Managing a Drug Crisis

If someone using this substance is in distress, our harm reduction guide covers crisis assessment, life-threatening response protocols, psychological crisis support, naloxone, Michigan medical amnesty, and integration.

Managing a Drug Crisis →